AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

Product Sales

Product Sales %Chg

Product Sales Common Size

Externalisation Revenue

Externalisation Revenue %Chg

Externalisation Revenue Common Size

Alliance Revenue

Alliance Revenue %Chg

Alliance Revenue Common Size

Product Revenue

Product Revenue %Chg

Product Revenue Common Size

Collaboration Revenue

Collaboration Revenue %Chg

Collaboration Revenue Common Size

Total Revenue

Total Revenue %Chg

Total Revenue Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Distribution Expense

Distribution Expense %Chg

Distribution Expense Common Size

Research and Development Expense

Research and Development Expense %Chg

Research and Development Expense Common Size

Selling, General and Administrative Expense

Selling, General and Administrative Expense %Chg

Selling, General and Administrative Expense Common Size

Profit on Disposal of Subsidiary

Profit on Disposal of Subsidiary %Chg

Profit on Disposal of Subsidiary Common Size

Other Operating Income

Other Operating Income %Chg

Other Operating Income Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Finance Income

Finance Income %Chg

Finance Income Common Size

Finance Expense

Finance Expense %Chg

Finance Expense Common Size

Share of After Tax Losses in Associates and Joint Ventures

Share of After Tax Losses in Associates and Joint Ventures %Chg

Share of After Tax Losses in Associates and Joint Ventures Common Size

Profit Before Tax

Profit Before Tax %Chg

Profit Before Tax Common Size

Taxation

Taxation %Chg

Taxation Common Size

Profit for the Period

Profit for the Period %Chg

Profit for the Period Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Interest and Investment Income

Interest and Investment Income %Chg

Interest and Investment Income Common Size

Interest Expense

Interest Expense %Chg

Interest Expense Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Consolidated Net Income

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	LTM	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
Total Revenues	58,127	54,073	45,811	44,351	37,417	26,617	24,384	22,090	22,465	23,002	24,708
Total Revenues %Chg	13.5%	18%	3.3%	18.5%	40.6%	9.2%	10.4%	-1.7%	-2.3%	-6.9%	-6.9%
Product Sales
Externalisation Revenue
Alliance Revenue
Collaboration Revenue
Product Revenue
Cost of Sales	10,240	10,207	8,268	12,391	12,437	5,299	4,921	4,936	4,318	4,126	4,646
Cost of Sales
Gross Profit	47,887	43,866	37,543	31,960	24,980	21,318	19,463	17,154	18,147	18,876	20,062
Gross Profit
Gross Profit Margin	82.4%	81.1%	82%	72.1%	66.8%	80.1%	79.8%	77.7%	80.8%	82.1%	81.2%
Selling, General & Administrative Expenses	20,420	20,532	19,755	18,955	15,680	11,693	12,021	10,362	10,543	9,739	11,451
Selling, General and Administrative Expense
Distribution Expense
Research & Development Expenses	15,047	13,583	10,935	9,762	9,736	5,991	6,059	5,932	5,757	5,890	5,997
Research and Development Expense
Other Operating Expenses	-381	-252	-1,340	-514	-1,492	-1,528	-1,541	-2,527	-1,830	-1,655	-1,500
Other Operating Income
Profit on Disposal of Subsidiary
Operating Profit	12,801	10,003	8,193	3,757	1,056	5,162	2,924	3,387	3,677	4,902	4,114
Operating Profit
Operating Margin	22%	18.5%	17.9%	8.5%	2.8%	19.4%	12%	15.3%	16.4%	21.3%	16.7%
Interest and Investment Income	289	458	344	95	43	87	172	138	113	67	46
Finance Income
Interest Expense	-1,639	-1,742	-1,626	-1,346	-1,300	-1,306	-1,432	-1,419	-1,508	-1,384	-1,075
Finance Expense
Non-Operating Income	-12	-28	-12	-5	-64	-27	-116	-113	-55	-33	-16
Share of After Tax Losses in Associates and Joint Ventures
Total Non-Operating Income	-1,362	-1,312	-1,294	-1,256	-1,321	-1,246	-1,376	-1,394	-1,450	-1,350	-1,045
Income Before Provision for Income Taxes	11,439	8,691	6,899	2,501	-265	3,916	1,548	1,993	2,227	3,552	3,069
Profit Before Tax
Provision for Income Taxes	2,035	1,650	938	-792	-380	772	321	-57	-641	146	243
Taxation
Consolidated Net Income	9,404	7,041	5,961	3,293	115	3,144	1,227	2,050	2,868	3,406	2,826
Profit for the Period
Net Income Attributable to Common Shareholders	9,404	7,041	5,961	3,293	115	3,144	1,227	2,050	2,868	3,406	2,826
Profit for the Period
Basic EPS	6.1	4.5	3.8	2.1	0.1	2.4	1	1.7	2.4	2.8	2.2
Diluted EPS	6	4.5	3.8	2.1	0.1	2.4	1	1.7	2.4	2.8	2.2
Basic Weighted Average Shares Outstanding	1,550.5	1,550	1,549	1,548	1,418	1,312	1,301	1,267	1,266	1,265	1,264
Total Shares Outstanding	1,550.7	1,550.5	1,550.2	1,549.8	1,549.4	1,312.7	1,312.1	1,267	1,266.2	1,265.2	1,264.1
Diluted Weighted Average Shares Outstanding	1,562.8	1,563	1,562	1,560	1,427	1,313	1,301	1,267	1,267	1,266	1,265
EBITDA	19,360	16,691	13,580	9,237	7,586	8,311	6,686	3,387	6,713	7,259	6,966
Effective Tax Rate	17.8%	19%	13.6%	-31.7%	143.4%	19.7%	20.7%	-2.9%	-28.8%	4.1%	7.9%